{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:29:49Z","timestamp":1787056189655,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jbior.2026.101169","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:46:31Z","timestamp":1778762791000},"page":"101169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in understanding the roles of TP53 mutations in pancreatic and hepatobiliary cancers"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-3156","authenticated-orcid":false,"given":"James A.","family":"McCubrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde Y.","family":"Follo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Manzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchiorre","family":"Cervello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppa","family":"Augello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbior.2026.101169_bib1","first-page":"2763","article-title":"Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma","volume":"8","author":"Abe","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.jbior.2026.101169_bib2","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1186\/s12885-025-15057-0","article-title":"TP53 c.730G>A pathogenic variant as a plausible candidate biomarker in pancreatic ductal adenocarcinoma patients from Karachi, Pakistan: a retrospective cohort study","volume":"25","author":"Adnan","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbior.2026.101169_bib3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/17520363.2024.2416888","article-title":"Proteomic biomarkers profiling in Pakistani pancreatic ductal adenocarcinoma population: a retrospective cohort study","volume":"18","author":"Ali","year":"2024","journal-title":"Biomark. Med."},{"key":"10.1016\/j.jbior.2026.101169_bib4","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1158\/1078-0432.CCR-20-0950","article-title":"Circulating tumor DNA is prognostic and potentially predictive of Eryaspase efficacy in second-line in patients with advanced pancreatic adenocarcinoma","volume":"26","author":"Bachet","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbior.2026.101169_bib5","article-title":"High-frequency mutations in TP53, AXIN1, CTNNB1, and KRAS, and polymorphisms in JAK1 genes among Mongolian HCC patients","volume":"2025 8","author":"Bold","year":"2025","journal-title":"Cancer Rep"},{"key":"10.1016\/j.jbior.2026.101169_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","article-title":"Therapeutic relevance of targeted sequencing in management of patients with advancedbiliary tract cancer: DNA damage repair gene mutations as a predictive biomarker","volume":"120","author":"Chae","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbior.2026.101169_bib7","article-title":"Targetingthe NPY\/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis","volume":"14","author":"Chambers","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jbior.2026.101169_bib8","article-title":"Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes","volume":"9","author":"Chen","year":"2021","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.jbior.2026.101169_bib9","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/2767-9764.CRC-23-0218","article-title":"p53R245W mutation fuels cancer initiation and metastases in NASH-driven liver tumorigenesis","volume":"29","author":"Dibra","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.jbior.2026.101169_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbior.2026.101169_bib12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4161\/cbt.11.11.15534","article-title":"Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer","volume":"11","author":"Feldmann","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"D1","key":"10.1016\/j.jbior.2026.101169_bib13","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbior.2026.101169_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"FOENIX-CCA2 StudyInvestigators. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbior.2026.101169_bib15","first-page":"4990","article-title":"Genomic mutation characteristics and prognosis of biliary tract cancer","volume":"15","author":"Guo","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.jbior.2026.101169_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2019.10.020","article-title":"Erythrocyte-encapsulated asparaginase(eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized Phase IIb trial","volume":"124","author":"Hammel","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbior.2026.101169_bib17","doi-asserted-by":"crossref","first-page":"14542","DOI":"10.18632\/aging.103501","article-title":"Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma","volume":"21","author":"Hou","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jbior.2026.101169_bib18","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/cam4.4571","article-title":"Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation","volume":"11","author":"Imamura","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.jbior.2026.101169_bib19","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202154275","article-title":"Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors","volume":"23","author":"Jiang","year":"2022","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jbior.2026.101169_bib20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jbior.2026.101169_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00535-015-1126-4","article-title":"Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features","volume":"51","author":"Kawai-Kitahata","year":"2016","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jbior.2026.101169_bib22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbior.2026.101169_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.jbior.2026.101169_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000527525","article-title":"Clinical implications of BRCA mutations in advanced biliary tract cancer","volume":"101","author":"Kim","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.jbior.2026.101169_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.18097\/PBMCR1495","article-title":"The role of the PPM1D gene in tumor pathogenesis","volume":"71","author":"Kucheryavenko","year":"2025","journal-title":"Biomed. Khim."},{"key":"10.1016\/j.jbior.2026.101169_bib28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/15384047.2022.2094666","article-title":"TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma","volume":"23","author":"Li","year":"2022","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jbior.2026.101169_bib29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/scisignal.adv4579","article-title":"The E3 ligase TRIM21 promotes progression of pancreatic ductal adenocarcinoma by down-regulating TAp63\u03b1 and derepressing IL20RB","volume":"18","author":"Li","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jbior.2026.101169_bib30","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jbior.2026.101169_bib31","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/gutjnl-2019-319616","article-title":"USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1\u03b1\/USP22 positive feedback loop upon TP53 inactivation","volume":"69","author":"Ling","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jbior.2026.101169_bib32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ebiom.2019.03.022","article-title":"Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma","volume":"42","author":"Long","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jbior.2026.101169_bib33","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1053\/j.gastro.2019.07.030","article-title":"Oncogenic KRAS reduces expression of FGF21 in acinar cells to promote pancreatic tumorigenesis in mice on a high-fat diet","volume":"157","author":"Luo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbior.2026.101169_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jhep.2020.07.036","article-title":"p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma","volume":"74","author":"Luo","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jbior.2026.101169_bib35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cancers11111659","article-title":"Circulating tumor cells in pancreatic cancer: current perspectives","volume":"11","author":"Martini","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbior.2026.101169_bib36","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.18632\/aging.204038","article-title":"Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR\/Ras\/Raf\/MEK, and PI3K\/mTORC1\/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties","volume":"14","author":"McCubrey","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jbior.2026.101169_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2024.101073","article-title":"TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors","volume":"95","author":"McCubrey","year":"2025","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2026.101169_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/738915","article-title":"Detection of TP53 R249 mutation in Iranian patients with pancreatic cancer","author":"Mohamadkhani","year":"2013","journal-title":"J. Oncol."},{"key":"10.1016\/j.jbior.2026.101169_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jbior.2026.101169_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jbior.2026.101169_bib41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2353\/ajpath.2008.070778","article-title":"Trp53 deletion stimulates the formation of metastatic pancreatic tumors","volume":"172","author":"Morton","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jbior.2026.101169_bib42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.molcel.2017.07.014","article-title":"Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport","volume":"17","author":"Nagarajan","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbior.2026.101169_bib44","first-page":"1636","article-title":"Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib","volume":"28","author":"Sakai","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbior.2026.101169_bib45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/jb\/mvp126","article-title":"PERIOD1 is an anti-apoptotic factor in human pancreatic and hepatic cancer cells","volume":"146","author":"Sato","year":"2009","journal-title":"J. Biochem."},{"key":"10.1016\/j.jbior.2026.101169_bib46","first-page":"19","article-title":"Hepatic hormone FGF21 and its analogues in clinical trials","volume":"8","author":"Shao","year":"2022","journal-title":"Chronic Dis. Transl. Med."},{"key":"10.1016\/j.jbior.2026.101169_bib47","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1111\/liv.14581","article-title":"TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy","volume":"40","author":"Shen","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.jbior.2026.101169_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110441","article-title":"G\u03b113 loss in Kras\/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin","volume":"38","author":"Shields","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbior.2026.101169_bib49","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1111\/bph.16438","article-title":"Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis","volume":"181","author":"Shin","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbior.2026.101169_bib50","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","article-title":"Current status and future perspectives of FGF21 analogues in clinical trials","volume":"35","author":"Siu","year":"2024","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.jbior.2026.101169_bib51","first-page":"2827","article-title":"Significance of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer. Curr. Issues Mol","volume":"46","author":"Stefanoudakis","year":"2024","journal-title":"Biol."},{"key":"10.1016\/j.jbior.2026.101169_bib52","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/s41388-024-03149-3","article-title":"PPM1D activity promotes cellular transformation by preventing senescence and cell death","volume":"43","author":"Stoyanov","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.jbior.2026.101169_bib53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/0008-5472.CAN-05-2305","article-title":"Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma","volume":"66","author":"Tuveson","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbior.2026.101169_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235623","article-title":"Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis","volume":"15","author":"Uesato","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jbior.2026.101169_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211033704","article-title":"Circulating TP53 mutations are associated with early tumor. progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX","volume":"13","author":"van der Sijde","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jbior.2026.101169_bib56","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1186\/s12967-023-04799-9","article-title":"Rictor mediates p53 deactivation to facilitate the malignant transformation of hepatocytes and promote hepatocarcinogenesis","volume":"18","author":"Wang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jbior.2026.101169_bib57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/15384047.2019.1685289","article-title":"Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells","author":"Wang","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jbior.2026.101169_bib58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jbior.2026.101169_bib59","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1053\/j.gastro.2010.11.034","article-title":"Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma","volume":"140","author":"Woo","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbior.2026.101169_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24103","article-title":"Quantitative detections of TP53 gene mutations improve the diagnosis and prognostic prediction of biliary tract cancers using droplet digital PCR","volume":"36","author":"Xiao","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.jbior.2026.101169_bib61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3892\/ol.2024.14664","article-title":"Prognostic prediction signature and molecular subtype for liver cancer: a CTC\/CTM-related gene prediction model and independent external validation","volume":"28","author":"Xu","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jbior.2026.101169_bib62","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4143\/crt.2019.533","article-title":"Prognostic value of TP53 mutation for transcatheter arterial chemoembolization failure\/refractoriness in HBV-related advanced hepatocellular carcinoma","volume":"52","author":"Xue","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.jbior.2026.101169_bib63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.gastro.2022.11.029","article-title":"Integrated multi-omics landscape of liver metastases","volume":"164","author":"Yang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbior.2026.101169_bib64","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3892\/or.2017.5494","article-title":"P53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma","volume":"37","author":"Ye","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jbior.2026.101169_bib66","article-title":"TP53\/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma","volume":"29","author":"Yu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jbior.2026.101169_bib67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12967-018-1707-0","article-title":"Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival","volume":"26","author":"Yu","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jbior.2026.101169_bib68","article-title":"LACTB suppresses liver cancer progression through regulation of ferroptosis","volume":"75","author":"Zeng","year":"2014","journal-title":"Redox Biol."},{"key":"10.1016\/j.jbior.2026.101169_bib69","article-title":"Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis","volume":"6","author":"Zhang","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbior.2026.101169_bib70","article-title":"A necroptosis-regulated model from single-cell analysis that predicts survival and identifies the pivotal role of MAGEA6 in hepatocellular carcinoma","volume":"13","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jbior.2026.101169_bib71","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41420-024-02196-9","article-title":"Targeting oncogenic MAGEA6 sensitizes triple negative breast cancer to doxorubicin through its autophagy and ferroptosis by stabling AMPK\u03b11","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Death Discov."}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492626000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492626000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:49:42Z","timestamp":1787053782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492626000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"alternative-id":["S2212492626000266"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2026.101169","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in understanding the roles of TP53 mutations in pancreatic and hepatobiliary cancers","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2026.101169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101169"}}